The European Cancer Congress 2013

esmo38 estro32

Abstracts not to be missed

Are you looking forward to another comprehensive four-day Congress at the ECC 2013 in Amsterdam?
If you haven’t decided which presentations to go and see yet, then fear not, we have made your life easier. We’ve asked a few of the Track Chairs to highlight a small selection from the ECC 2013 programme.


Basic Science

  • Abstract title: Integrative analysis of genomic and transcriptomic data reveals the presence of a novel molecular class shared by all cancer entities
    Abstract number: 504
    Speaker: Manfred Beleut, CH
  • Abstract title: Genome-wide identification of stromal metastasis regulators in breast cancer mouse models (Winner of ECCO/EJC Young Investigator's Award)
    Abstract number: 503
    Speaker: Thomas Geiger, US


Breast Cancer Early

  • Abstract title: The 70-gene signature predicts the risk of locoregional recurrence after adequate breast surgery
    Abstract number: 1855
    Speaker: Matthijs Nijenhuis, NL
  • Abstract title: Clinical and pathological response after neoadjuvant chemotherapy with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer
    Abstract number: 1858
    Speaker: Ayoub Charehbili, NL
  • Abstract title: PI3KCA mutations and correlation with pCR in the NeoALTTO trial (BIG 01-06)
    Abstract number: 1859
    Speaker: José Baselga, US


Breast Cancer Advanced

  • Abstract title: Circulating tumor cells before and during therapy in metastatic breast cancer: an individual patient data pooled analysis of European studies
    Abstract number: 1854
    Speaker: François-Clement Bidard, FR
  • Abstract title: Complex tumor genomes inferred from plasma DNA of patients with metastatic breast cancer by whole-genome sequencing
    Abstract number: 1852
    Speaker: Martian Auer, AT


Cancer in the Older Patient

  • Abstract title: Performance of two geriatric screening tools in older cancer patients
    Abstract number: 1551
    Speaker: Cindy Kenis, B
  • Abstract title: Predicting outcome in onco-geriatric surgical patients: screening tools versus the comprehensive geriatric assessment
    Abstract number: 1550
    Speaker: Monique Huisman, NL
  • Abstract title: Hormone receptor positive breast cancer in patients aged 75 years and older: limited external validity of clinical trial results
    Abstract number: 1554
    Speaker: Willemien Van de Water, NL
  • Abstract title: Low grade toxicities can have significant impact on chemotherapy completion in older patients
    Abstract number: 1555
    Speaker: Tania Kalsi, UK


Colorectal I

  • Abstract title: Intensified follow-up in colorectal cancer patients using frequent carcino-embronic antigen (CEA) measurements and CEA-triggered imaging
    Abstract number: 2151
    Speaker: Charlotte Verberne, NL
  • Abstract title: Differences in circumferential resection margin involvement after abdominoperineal excision and low anterior resection no longer significant
    Abstract number: 2152
    Speaker: Nicoline van Leersum, NL
  • Abstract title: Preoperative radiotherapy with a simultaneous integrated boost compared to chemoradiotherapy for T3-4 rectal cancer: interim analysis of a multicentric randomized trial
    Abstract number: 2153
    Speaker: Mark De Ridder, B
  • Abstract title: Health-related quality of life of patients 14 years after short-term preoperative radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial
    Abstract number: 2154
    Speaker: Lisette Wiltink, NL


Colorectal II

  • Abstract title: Effects of regorafenib therapy on health-related quality of life in patients with metastatic colorectal cancer in the phase III CORRECT study
    Abstract number: 2156
    Speaker: Salvatore Siena, IT
  • Abstract title: The impact of young age on survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program
    Abstract number: 2158
    Speaker: Christopher Lieu, US
  • Abstract title: Prognostic impact of specific KRAS mutations in codon 12 and 13 in 2,165 BRAF-wildtype colon cancers: results from NCCTG (Alliance) trial N0147
    Abstract number: 2160
    Speaker: Harry Yoon, US
  • Abstract title: Evaluation of PIK3CA mutation as a predictor of benefit from NSAID therapy in colorectal cancer
    Abstract number: 2161
    Speaker: David Church, UK



  • Abstract title: CA184-043: A randomized, multicenter, double-blind phase 3 trial comparing overall survival (OS) in patients (pts) with post-docetaxel castration-resistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (ipi) vs placebo (pbo), each following single-dose radiotherapy (RT)
    Abstract number: 2850
    Speaker: Winald R. Gerritsen, NL
  • Abstract title: An open-label, phase I/II safety, pharmacokinetic, and proof-of concept study of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)
    Abstract number: 2853
    Speaker: Karim Fizazi, FR
  • Abstract title: The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC)
    Abstract number: 2854
    Speaker: Eleni Efstathiou, US
  • Abstract title: Evaluation of a composite biomarker panel including circulating tumor cell (CTC) enumeration as a surrogate for survival in metastatic castration-resistant prostate cancer (mCRPC)
    Abstract number: 2861
    Speaker: Howard Scher, US


Head and Neck Cancer

  • Abstract title: Association of XPF and HPV among squamous cell head and neck cancer tumors: biomarker analysis of ECOG 3303
    Abstract number: 3152
    Speaker: Ranee Mehra, US
  • Abstract title: Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: sub-analysis of the phase III DECISION trial
    Abstract number: 3155
    Speaker: Marcia Brose, US


Lung Cancer - Metastatic and Localised/Systemic

  • Abstract title: Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies
    Abstract number: 3401
    Speaker: D. Ross Camidge, US
  • Abstract title: Pemetrexed (PEM) and cisplatin (CIS) with concurrent thoracic radiation after PEM+CIS induction in patients (pts) with unresectable locally advanced (LA) nonsquamous non-small cell lung cancer (NS-NSCLC): primary results of a phase II study
    Abstract number: 3402
    Speaker: Pilar Garrido, ES
  • Abstract title: Resistance training in patients with radically treated respiratory cancer: a prospective randomized multi-center study (REINFORCE)
    Abstract number: 3404
    Speaker: Jan Van Meerbeeck, B


Lung Cancer - Metastatic

  • Abstract title: Evaluation of protein expression by immunohistochemistry in non-small cell lung cancer (pharmacogenoscan study)
    Abstract number: 3406
    Speaker: Anne-Claire Toffart, FR
  • Abstract title: Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1)
    Abstract number: 3408
    Speaker: Jean-Charles Soria, FR
  • Abstract title: MARQUEE: a randomized, double-blind, placebo-controlled, phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small-cell lung cancer (NSCLC)
    Abstract number: 3410
    Speaker: Silvia Novello, IT


Non Colorectal Cancer

  • Abstract title: Pilot study for a European upper GI cancer audit (EURECCA Upper GI)
    Abstract number: 2451
    Speaker: Johan Dikken, NL
  • Abstract title: Comprehensive arrays for expression profiling identify key microRNA to distinguish short and long survivors among resected pancreatic cancers patients
    Abstract number: 2455
    Speaker: Elisa Giovannetti, NL


Public Health and Epidemiology

  • Abstract title: Discrepancies in cancer incidence and mortality and its relation to health expenditure among the 27 European Union member states
    Abstract number: 1400
    Speaker: Felipe Ades Moraes, B
  • Abstract title: The effect of metformin and sulfonylurea derivatives use after colorectal cancer diagnosis on survival
    Abstract number: 1403
    Speaker: Marjolein Zanders, NL
  • Abstract title: Trends in colorectal cancer mortality and screening activities in European countries
    Abstract number: 1405
    Speaker: Philippe Autier, FR



  • Abstract title: Targeting hypoxia to enhance the anti-tumour effect of a stereotactic radiation schedule
    Abstract number: 1050
    Speaker: Michael Horsman, DK
  • Abstract title: EGFR-amplification corralates with response to combined treatment of fractionated irradiation and EGFR-inhibition in HNSCC tumour xenografts
    Abstract number: 1051
    Speaker: Kristin Gurtner, DE
  • Abstract title: Myeloid cells as a novel determinant of hypoxic radioresponse in colorectal cancer cells through L-arginine turnover
    Abstract number: 1052
    Speaker: Mark De Ridder, B
  • Abstract title: Reduction of heart dose during left breast cancer radiotherapy: comparison between respiratory gating RT and IMRT
    Abstract number: 1054
    Speaker: Giuseppe R. D'Agostino, IT
PRINT THIS PAGE Page last modified: